MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Phase 4
Conditions
Brain Ischemia
Intracranial Hemorrhages
Interventions
Drug: cilostazol
Drug: Probucol
Drug: Aspirin
Drug: Placebo of aspirin
Drug: placebo of cilostazol
Device: Intima-medial thickness
First Posted Date
2015-06-26
Last Posted Date
2015-12-24
Lead Sponsor
Asan Medical Center
Target Recruit Count
800
Registration Number
NCT02483169

Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting

Phase 2
Completed
Conditions
Stable Angina
Coronary Artery Bypass Surgery
Interventions
First Posted Date
2015-06-26
Last Posted Date
2018-03-08
Lead Sponsor
Karolinska University Hospital
Target Recruit Count
45
Registration Number
NCT02482857

Adjuvant Aspirin Treatment for Colon Cancer Patients

Phase 3
Completed
Conditions
Colon Cancer
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2015-06-10
Last Posted Date
2024-12-02
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
114
Registration Number
NCT02467582
Locations
🇨🇭

HFR-Hôpital cantonal, Fribourg, Switzerland

🇩🇪

pioh KÖLN, Köln, Germany

🇩🇪

Klinikum Ludwigsburg, Ludwigsburg, Germany

and more 49 locations

CV004-007 Thrombosis Chamber Study

Phase 1
Completed
Conditions
Thrombosis
Interventions
First Posted Date
2015-05-08
Last Posted Date
2016-09-08
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
42
Registration Number
NCT02439190
Locations
🇬🇧

Local Institution, Edinburgh, Scotland, United Kingdom

Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization

Phase 3
Withdrawn
Conditions
Peripheral Arterial Disease
Endovascular Procedures
Interventions
First Posted Date
2015-05-05
Last Posted Date
2019-10-07
Lead Sponsor
University Hospitals Cleveland Medical Center
Registration Number
NCT02433587
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

Apixaban for Treatment of Embolic Stroke of Undetermined Source

Phase 3
Completed
Conditions
Embolic Stroke of Undetermined Source
Interventions
First Posted Date
2015-04-27
Last Posted Date
2021-10-13
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
352
Registration Number
NCT02427126
Locations
🇩🇪

Regiomed Kliniken Coburg GmbH Abt. II, Coburg, Germany

🇩🇪

Neurologie, Klinikum Friedrichshafen GmbH, Friedrichshafen, Germany

🇩🇪

Carl von Basedow KlinikumSaalekreis gGmbH, Merseburg, Germany

and more 13 locations

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

Phase 2
Terminated
Conditions
Recurrent Prostate Carcinoma
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Interventions
Drug: Aspirin
Other: Laboratory Biomarker Analysis
Other: Placebo
Drug: Metformin Hydrochloride
First Posted Date
2015-04-20
Last Posted Date
2023-02-08
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
27
Registration Number
NCT02420652
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Dose-escalation, Repeated and Single Oral Dosing Study

Phase 1
Terminated
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2015-04-17
Last Posted Date
2019-02-15
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
104
Registration Number
NCT02419820

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Phase 4
Completed
Conditions
Acute Coronary Syndromes
Interventions
Other: Acetylsalicylic acid placebo
Drug: vitamin K antagonist
Drug: Apixaban
Drug: Acetylsalicylic acid
First Posted Date
2015-04-14
Last Posted Date
2020-06-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
4614
Registration Number
NCT02415400
Locations
🇺🇸

Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States

🇺🇸

Southern Arizona VA Health Care System, Tucson, Arizona, United States

🇺🇸

Saint Lukes Idaho Cardiology Associates, Boise, Idaho, United States

and more 90 locations

Ticagrelor and Peripheral Arterial Disease

Phase 4
Terminated
Conditions
Peripheral Arterial Disease
Interventions
Procedure: Percutaneous Peripheral Intervention
Device: Optical Coherence Tomography
Other: Ankle Brachial Index
Other: Six minute walk distance
Drug: Aspirin + Ticagrelor
Drug: Aspirin
First Posted Date
2015-04-02
Last Posted Date
2019-01-11
Lead Sponsor
Arkansas Heart Hospital
Target Recruit Count
26
Registration Number
NCT02407314
Locations
🇺🇸

Arkansas Heart Hospital, Little Rock, Arkansas, United States

© Copyright 2025. All Rights Reserved by MedPath